MedWatch

Novo Holdings eyes opportunities as biotech bubble bursts

After years of speculation and premature IPOs, the biotech bubble has burst, says CEO of Novo Holdings Kasim Kutay, who’s now fishing in the troubled waters, saying that the downswing might not last.

Kasim Kutay, CEO of Novo Holdings | Photo: Novo Holdings / PR

In 2021, Novo Holdings could once again report that few life science players are better at making money than the holding company itself, which booked a total income of EUR 5bn in 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs